These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39050978)

  • 21. Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
    Verkerk K; Geurts BS; Zeverijn LJ; van der Noort V; Verheul HMW; Haanen JBAG; van der Veldt AAM; Eskens FALM; Aarts MJB; van Herpen CML; Jalving M; Gietema JA; Devriese LA; Labots M; Barjesteh van Waalwijk van Doorn-Khosrovani S; Smit EF; Bloemendal HJ
    Lancet Reg Health Eur; 2024 Apr; 39():100875. PubMed ID: 38464480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
    Waterhouse D; Iadeluca L; Sura S; Wilner K; Emir B; Krulewicz S; Espirito J; Bartolome L
    Target Oncol; 2022 Jan; 17(1):25-33. PubMed ID: 34964940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
    Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
    Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis.
    Nardone V; Napolitano S; Gagliardi F; Esposito A; Caraglia F; Briatico G; Scharf C; Ronchi A; D'Onofrio I; D'Ippolito E; Russo A; Belfiore MP; Franco R; Argenziano G; Ciardiello F; Reginelli A; Cappabianca S; Troiani T
    J Am Acad Dermatol; 2024 Oct; 91(4):678-683. PubMed ID: 38885840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma.
    Valentin J; Gérard E; Ferte T; Prey S; Dousset L; Dutriaux C; Beylot-Barry M; Pham-Ledard A
    J Geriatr Oncol; 2021 Sep; 12(7):1110-1113. PubMed ID: 33736973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma.
    Vo TT; Espirito JL; Boyd M; Gumuscu B; Chirovsky D; Robert NJ; Swaby RF; Zhou W; Cowey CL
    Future Oncol; 2022 Jun; 18(17):2087-2099. PubMed ID: 35240857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
    Rischin D; Hughes BGM; Basset-Séguin N; Schadendorf D; Bowyer S; Trabelsi Messai S; Meier F; Eigentler TK; Casado Echarren V; Stein B; Beylot-Barry M; Dalac S; Dréno B; Migden MR; Hauschild A; Schmults CD; Lim AM; Yoo SY; Paccaly AJ; Papachristos A; Nguyen JH; Okoye E; Seebach F; Booth J; Lowy I; Fury MG; Guminski A
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
    Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
    Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
    Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P
    Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
    Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
    Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Harris BN; Pipkorn P; Nguyen KNB; Jackson RS; Rao S; Moore MG; Farwell DG; Bewley AF
    JAMA Otolaryngol Head Neck Surg; 2019 Feb; 145(2):153-158. PubMed ID: 30570645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world study of patients with locally advanced HNSCC in the community oncology setting.
    Black CM; Ramakrishnan K; Nadler E; Tseng WY; Wentworth C; Murphy J; Fulcher N; Wang L; Alexander M; Patton G
    Front Oncol; 2023; 13():1155893. PubMed ID: 37664029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic.
    Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M
    Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
    Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
    Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
    Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center.
    Denaro N; Passoni E; Indini A; Nazzaro G; Beltramini GA; Benzecry V; Colombo G; Cauchi C; Solinas C; Scartozzi M; Marzano AV; Garrone O
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma.
    McLean LS; Lim AM; Bressel M; Thai AA; Rischin D
    Drugs Aging; 2024 Mar; 41(3):271-281. PubMed ID: 38446342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
    Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Yoo SY; Mathias M; Han H; Seebach F; Lowy I; Fury MG; Rischin D
    Lancet Oncol; 2023 Nov; 24(11):1196-1205. PubMed ID: 37875144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
    Rischin D; Migden MR; Lim AM; Schmults CD; Khushalani NI; Hughes BGM; Schadendorf D; Dunn LA; Hernandez-Aya L; Chang ALS; Modi B; Hauschild A; Ulrich C; Eigentler T; Stein B; Pavlick AC; Geiger JL; Gutzmer R; Alam M; Okoye E; Mathias M; Jankovic V; Stankevich E; Booth J; Li S; Lowy I; Fury MG; Guminski A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.